financetom
Business
financetom
/
Business
/
RCF Q2 net profit slumps 81% to ₹51 crore, revenue dips 26% to ₹4,155 crore
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
RCF Q2 net profit slumps 81% to ₹51 crore, revenue dips 26% to ₹4,155 crore
Nov 10, 2023 1:22 PM

State-run Rashtriya Chemicals and Fertilizers Ltd (RCF) on Friday (November 10) reported an 80.5% year-on-year (YoY) decline in net profit at ₹51 crore for the second quarter that ended September 30, 2023.

In the corresponding quarter last year, Rashtriya Chemicals and Fertilizers posted a net profit of ₹261.9 crore, the company said in a regulatory filing.

The company's revenue from operations declined 25.5% to ₹4,155.2 crore as against ₹5,576 crore in the corresponding period of the preceding fiscal.

Also Read: Biocon Q2 Results 2023: Net profit jumps 111% to ₹173 crore, beats estimates

At the operating level, EBITDA tanked 73.9% to ₹105.9 crore in the second quarter of this fiscal over ₹405 crore in the corresponding period in the previous fiscal.

EBITDA margin stood at 2.6% in the reporting quarter as compared to 7.3% in the corresponding period in the previous fiscal. EBITDA is earnings before interest, tax, depreciation, and amortization.

The results came after the close of the market hours. Shares of Rashtriya Chemicals and Fertilizers Ltd ended at ₹127.65, up by ₹ 0.100, or 0.078 percent on the BSE.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Terns Pharmaceuticals Prices $150.2 Million Public Offering
Terns Pharmaceuticals Prices $150.2 Million Public Offering
Sep 11, 2024
03:56 AM EDT, 09/11/2024 (MT Newswires) -- Terns Pharmaceuticals ( TERN ) said Tuesday it has priced a public offering of about 11.9 million common shares at $10.50 per share and pre-funded warrants to purchase 2.4 million common shares at $10.4999 per pre-funded warrant. Gross proceeds from the offering, expected to close Thursday, are estimated to be about $150.2 million,...
China's Midea Group to price shares at top of range in Hong Kong listing, sources say
China's Midea Group to price shares at top of range in Hong Kong listing, sources say
Sep 11, 2024
SYDNEY (Reuters) - Chinese home appliance maker Midea Group is set to price shares at the top of an indicative range to raise at least $3.46 billion in a Hong Kong listing, said three people with direct knowledge of the matter. Book building for the deal has been accelerated to close on Wednesday, the people said. Midea has an option...
MOVES-Goldman Sachs appoints three co-heads of Asia M&A to bolster regional presence
MOVES-Goldman Sachs appoints three co-heads of Asia M&A to bolster regional presence
Sep 11, 2024
HONG KONG, Sept 11 (Reuters) - Goldman Sachs ( GS ) has appointed Raghav Maliah, Yoshihiko Yano and Ed Wittig as co-heads of mergers and acquisitions in Asia Pacific to expand and deepen deals coverage in the region, according to an internal memo on Tuesday seen by Reuters. Wittig is joining the bank's Asia team later this year from New...
Regeneron, Sanofi's Dupixent Drug Meets Main Goal in 2 Late-Stage Trials
Regeneron, Sanofi's Dupixent Drug Meets Main Goal in 2 Late-Stage Trials
Sep 11, 2024
04:08 AM EDT, 09/11/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Wednesday that a confirmatory phase 3 study of Dupixent met primary and key secondary goals in treating patients with uncontrolled, biologic-naive chronic spontaneous urticaria receiving background therapy with antihistamines. The study showed that Dupixent added to standard-of-care reduced itch severity from baseline...
Copyright 2023-2026 - www.financetom.com All Rights Reserved